Pulling SEC filings + quote and writing the call…
RVMD
Revolution Medicines, Inc.
Next earnings Aug 4, 2026 (after close) · consensus $-1.99 EPS, $19.5M rev
Last earnings +2.6% on 2026-05-06
$165.74
▲ +1.68%$162.99▲ +309.83%
over 1Y
L $34.70EODHDH $163.68
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.7%
1W+9.2%
1M+10.7%
3M+64.2%
YTD+106.3%
1Y+309.8%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 27 analysts
Strong Buy
Pre-revenue RAS-cancer bet with real FDA breakthrough tags, but ~$900M annual burn and a ~$32B price make it a speculative avoid.
Revolution Medicines is, in its own words, "a clinical-stage precision oncology company with a limited operating history and no products approved for commercial sale." The financials confirm it: product revenue was $0.00 in both FY2024 and FY2025, the net loss widened to -$1.13B (from -$600M), and the accumulated deficit now stands at -$2.87B. R&D spending jumped 66.7% to $987M as the company pushes its RAS(ON) pipeline forward. There is no fundamentals-based valuation case here — diluted EPS is -$5.95 and ROE is -69.3% by design. This is a binary clinical bet, not a profitable business.
Sources: SEC EDGAR (CIK 0001628171, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/20/2026, 12:23:55 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.